A Comprehensive Board Review in Hematology and Medical Oncology 09
September 21–26, 2009
Robert C. Hickey Auditorium
11th Floor, R. Lee Clark Clinic
1515 Holcombe Boulevard
The University of Texas M. D. Anderson Cancer Center
Houston, Texas
Sept. 21–23, 2009: Benign and Malignant Hematology
Sept. 23–26, 2009: Malignant Hematology and Medical Oncology
General Information
- Brochure (pdf)
- Conference Agenda
- Committee and Speaker Information
- Registration Information
- Material Order Information
- Hotel & Transportation Information
- Houston Entertainment
Educational Objectives
After attending the course, participants should be able to
- describe and utilize current standards of care for patients with cancer, blood disorders and malignancies;
- define molecular determinants of cancer risk and apply this knowledge in practice;
- demonstrate proficiency of knowledge in hematology and medical oncology;
- apply knowledge gained to prepare for the hematology and medical oncology subspecialty and recertification examinations in hematology and medical oncology;
- provide an update on recent advances in management for the practicing physician.
Target Audience
The course should be of value to physicians, medical hematologists and oncologists, APNs, physician assistants, and nurses.
Educational Methods
- Lectures
- Case-based Question-and-Answer Sessions (in board examination format)
- Syllabi (hard copy and CD-ROM)
Evaluation
A course evaluation form will provide participants with the opportunity to review each session and speaker, to identify future educational needs, and to comment on any perceived commercial bias in the presentations.
Goal
The course is a 6-day comprehensive review of current standards and practices in the management of patients with blood disorders and malignancy. The course is designed with breadth and depth sufficient to enable the participant to effectively prepare for the American Board of Internal Medicine certification and recertification examinations in
Hematology and Medical Oncology. Advances in clinical pharmacology, molecular genetics and risk assessment, and radiation oncology will be included.
Accreditation/Credit Designation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Texas M. D. Anderson Cancer Center and Baylor College of Medicine. The University of Texas M. D. Anderson Cancer Center is accredited by the ACCME to provide continuing medical education for physicians.
The University of Texas M. D. Anderson Cancer Center designates this educational activity for a maximum of 46.50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CME Certificates and Attendance
Verification Certificates Certificates awarding AMA PRA Category 1 Credit™ or certificates documenting attendance will be distributed to participants when an individual departs the conference.
To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME Verification Form. Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

